trending Market Intelligence /marketintelligence/en/news-insights/trending/qrychj7javo2_l86ojlcgg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Evolent Health issues Q2 guidance

Amid Q1 APAC Fintech Funding Slump, Payment Companies Drove Investments

Paypal Well-Positioned To Gain Share In COVID-Related Digital Payments Shift

Digital Banking Battles Will Play Out In Southeast Asias Shopping Cart

Report: Kashkari Says Fed In Holding Pattern But Rate Cut Still Possible

Evolent Health issues Q2 guidance

Evolent Health issued guidance for the second quarter and reaffirmed its outlook for full year 2018.

For the second quarter, the company expects adjusted revenue of about $139.0 million to $143.0 million, and adjusted EBITDA of approximately $3.0 million to $5.0 million.

For the first quarter, Evolent Health reported a net loss attributable to the company of $13.6 million, or 18 cents per share, compared to a net loss of $18.0 million, or 34 cents per share, in the year-ago period.

For full year 2018, the company continues to expect adjusted revenue of approximately $565.0 million to $585.0 million, and adjusted EBITDA of about $18.0 million to $23.0 million.